These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1059 related articles for article (PubMed ID: 29118007)

  • 21. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.
    Homet Moreno B; Ribas A
    Br J Cancer; 2015 Apr; 112(9):1421-7. PubMed ID: 25856776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Where does PD-1 blockade fit in HL therapy?
    Herrera AF
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
    Song MK; Park BB; Uhm J
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
    Fang XN; Fu LW
    Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
    He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
    Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now.
    Juárez-Salcedo LM; Sandoval-Sus J; Sokol L; Chavez JC; Dalia S
    Crit Rev Oncol Hematol; 2017 May; 113():52-62. PubMed ID: 28427522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
    Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP
    Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 30. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
    Deng S; Hu Q; Zhang H; Yang F; Peng C; Huang C
    Mol Cancer Ther; 2019 May; 18(5):900-908. PubMed ID: 30824609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas.
    Bednarska K; Nath K; Nicol W; Gandhi MK
    Blood Rev; 2021 Nov; 50():100832. PubMed ID: 33896649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
    Chen BJ; Chapuy B; Ouyang J; Sun HH; Roemer MG; Xu ML; Yu H; Fletcher CD; Freeman GJ; Shipp MA; Rodig SJ
    Clin Cancer Res; 2013 Jul; 19(13):3462-73. PubMed ID: 23674495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art.
    Zanelli M; Fragliasso V; Parente P; Bisagni A; Sanguedolce F; Zizzo M; Broggi G; Ricci S; Palicelli A; Foroni M; Gozzi F; Gentile P; Morini A; Koufopoulos N; Caltabiano R; Cimino L; Fabozzi M; Cavazza A; Neri A; Ascani S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
    Barta SK; Zain J; MacFarlane AW; Smith SM; Ruan J; Fung HC; Tan CR; Yang Y; Alpaugh RK; Dulaimi E; Ross EA; Campbell KS; Khan N; Siddharta R; Fowler NH; Fisher RI; Oki Y
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):356-364.e3. PubMed ID: 31029646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
    Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.